Phase I Study of CDK 4-6 Inhibitor PD-0332991 in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors

Official Title: Phase I Study of CDK 4-6 Inhibitor PD-0332991 in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors

This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment. Palbociclib isethionate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT02255461
Goldman, Stewart, MD
Interventional
No

Contact Information:

312.227.4090